olivLaw · US equity research
Owlet, Inc. OWLT
Measuring & Controlling Devices, NEC · SIC 3829 · Vertical: Measuring & Controlling Devices, NEC (SIC 3829)
Owlet is a pediatric health platform that sells FDA-cleared wearable monitors for home use, paired with a subscription service built on pediatric sleep and health data. The company grew revenue 35.4% in fiscal 2025, reported its first full year of positive Adjusted EBITDA, and in the first half of 2026 shifted its focus toward growing its subscriber base.
At the close of 04 Nov 2026, Owlet, Inc. (OWLT) stock was 4.53 USD (+7.09% on the day), with market capitalisation 132.4 m USD, beta 1.49, 52-week range 4.03–16.52 USD. Latest reported quarter (Q2 2026): revenue of 33.9 m USD (+29.9% YoY), net income of -620.0 k USD, diluted EPS -0.05 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 52.7
- neutral
- Bollinger (20, 2)
- 3.88 – 4.74
- in the upper half of the band · %B 0.76 · band width 19.9%
- SMA 50 / 200
- 4.70 / 6.25
- downtrend (price < SMA50 < SMA200)
- MACD (12, 26, 9)
- -0.15 / -0.20
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | −10.5% | −1.1% | −9.4 pp | — |
| 3 months | −17.6% | −0.5% | −17.2 pp | — |
| 6 months | −12.9% | +4.4% | −17.3 pp | — |
| Year to date | −72.0% | +12.3% | −84.3 pp | — |
| 1 year | −44.8% | +13.5% | −58.3 pp | −30.9% |
| 3 years | +4.6% | +76.4% | −71.8 pp | +16.9% |
| 5 years | −91.3% | +63.7% | −155.0 pp | — |
Price returns, dividends excluded.
Quarterly results
Latest quarter: Q2 2026 · 30 Jun 2026
Quarterly margins
Quarterly statements · USD
| Fiscal year | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 22.1 m | 20.5 m | 21.6 m | 26.1 m | 32.0 m | 26.1 m | 22.5 m | 33.9 m |
| Cost of revenue | 10.6 m | 9.5 m | 9.8 m | 12.7 m | 15.8 m | 13.9 m | 10.2 m | 12.0 m |
| Gross profit | 11.5 m | 11.0 m | 11.8 m | 13.4 m | 16.2 m | 12.2 m | 12.2 m | 21.8 m |
| Research & development | 2.6 m | 2.5 m | 2.9 m | 3.7 m | 3.8 m | 3.7 m | 3.9 m | 4.6 m |
| Operating income | -4.8 m | -7.4 m | -2.2 m | -1.7 m | 1.3 m | -5.7 m | -5.4 m | 1.7 m |
| Depreciation & amortisation | 117.0 k ≈ | 122.0 k | 119.0 k | 109.0 k ≈ | 141.0 k ≈ | 152.0 k | 185.0 k | 211.0 k ≈ |
| Interest expense | 136.0 k | 1.5 m | 385.0 k | 282.0 k | 95.0 k | 47.0 k | 0 | 0 |
| Pre-tax income | -5.6 m | -9.0 m | 3.5 m | -37.4 m | 4.2 m | -10.0 m | -3.2 m | -610.0 k |
| Income tax | 0 | 32.0 k | 12.0 k | 33.0 k | 9.0 k | -26.0 k | 7.0 k | 10.0 k |
| Net income | -5.6 m | -9.1 m | 3.5 m | -37.4 m | 4.2 m | -9.1 m | -3.2 m | -620.0 k |
| Diluted EPS | -0.61 | -0.60 ≈ | 0.14 | -2.35 | -0.05 | -0.37 ≈ | -0.24 | -0.05 |
| Operating cash flow | -7.5 m ≈ | 3.0 m | -5.9 m | -2.2 m ≈ | -2.2 m ≈ | -452.0 k | -5.0 m | -92.0 k ≈ |
| Capex | -1.0 k ≈ | 33.0 k | 4.0 k | 61.0 k ≈ | 9.0 k ≈ | 199.0 k | 15.0 k | 539.0 k ≈ |
≈ derived quarter (cumulative difference / share-days average)
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Fiscal years
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 75.4 m | 75.8 m | 69.2 m | 54.0 m | 78.1 m | 105.7 m |
| Revenue YoY | unavailable | +0.6% | −8.8% | −22.0% | +44.5% | +35.4% |
| Net income | -10.5 m | -71.7 m | -79.3 m | -32.9 m | -12.5 m | -39.7 m |
| Net income YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| Diluted EPS | -0.48 | -1.13 | -9.98 | -4.53 | -1.57 | -2.31 |
| Diluted EPS YoY | unavailable | unavailable | unavailable | unavailable | unavailable | unavailable |
| net % | -14.0% | -94.5% | -114.6% | -60.9% | -16.1% | -37.5% |
| Free cash flow | -1.1 m | -41.5 m | -82.0 m | -23.5 m | -11.2 m | -11.1 m |
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 35.5 m USD
- Financial debt
- 13.0 m USD
- Net debt
- -22.4 m USD
- Equity
- 19.0 m USD
- Total assets
- 85.6 m USD
- Debt / equity
- 0.68x
- Current ratio
- 1.85x
- ROE
- unavailable
- ROA
- -58.7%
- FCF margin
- -10.5%
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 75.4 m | 75.8 m | 69.2 m | 54.0 m | 78.1 m | 105.7 m | SEC (XBRL)· 09 Mar 2026verified |
| Cost of revenue | 39.5 m | 40.8 m | 45.9 m | 31.4 m | 38.7 m | 52.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Gross profit | 35.9 m | 35.1 m | 23.3 m | 22.6 m | 39.3 m | 53.5 m | SEC (XBRL)· 09 Mar 2026verified |
| Research & development | 10.5 m | 21.4 m | 27.9 m | 10.3 m | 9.8 m | 14.1 m | SEC (XBRL)· 09 Mar 2026verified |
| Operating income | -7.0 m | -55.8 m | -84.6 m | -28.6 m | -20.2 m | -8.3 m | SEC (XBRL)· 09 Mar 2026verified |
| Depreciation & amortisation | 873.0 k | 1.1 m | 1.4 m | 842.0 k | 452.0 k | 521.0 k | SEC (XBRL)· 09 Mar 2026verified |
| EBITDA | -6.1 m ≈ | -54.7 m ≈ | -83.2 m ≈ | -27.8 m ≈ | -19.8 m ≈ | -7.7 m ≈ | SEC (XBRL)· 09 Mar 2026derived |
| Interest expense | 1.4 m | 1.8 m | 1.1 m | 3.2 m | 1.6 m | 809.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Pre-tax income | -10.5 m | -71.7 m | -79.3 m | -32.9 m | -12.5 m | -39.7 m | SEC (XBRL)· 09 Mar 2026verified |
| Income tax | 20.0 k | 31.0 k | 29.0 k | 10.0 k | 54.0 k | 28.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Net income | -10.5 m | -71.7 m | -79.3 m | -32.9 m | -12.5 m | -39.7 m | SEC (XBRL)· 09 Mar 2026verified |
| Diluted EPS | -0.48 | -1.13 | -9.98 | -4.53 | -1.57 | -2.31 | SEC (XBRL)· 09 Mar 2026verified |
| Weighted average diluted shares | 22.0 m | 63.2 m | 8.0 m | 8.3 m | 11.0 m | 18.1 m | SEC (XBRL)· 09 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating income + Depreciation & amortisation.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 17.0 m | 95.1 m | 11.2 m | 16.6 m | 20.2 m | 35.5 m | SEC (XBRL)· 09 Mar 2026verified |
| Receivables | 10.5 m | 10.5 m | 16.0 m | 14.0 m | 12.1 m | 22.9 m | SEC (XBRL)· 09 Mar 2026verified |
| Inventories | 7.9 m | 18.0 m | 18.5 m | 6.5 m | 10.5 m | 15.3 m | SEC (XBRL)· 09 Mar 2026verified |
| Current assets | 37.6 m | 135.8 m | 51.3 m | 39.9 m | 46.1 m | 81.9 m | SEC (XBRL)· 09 Mar 2026verified |
| Property, plant & equipment, net | 1.7 m | 1.9 m | 1.1 m | 377.0 k | 102.0 k | 295.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Intangibles (excl. goodwill) | 605.0 k | 1.7 m | 2.3 m | 2.2 m | 975.0 k | 1.4 m | SEC (XBRL)· 09 Mar 2026verified |
| Total assets | 40.1 m | 140.0 m | 58.1 m | 44.1 m | 49.5 m | 85.6 m | SEC (XBRL)· 09 Mar 2026verified |
| Accounts payable | 16.4 m | 27.8 m | 30.4 m | 13.7 m | 11.3 m | 12.0 m | SEC (XBRL)· 09 Mar 2026verified |
| Short-term debt | 2.0 m | 8.5 m | 10.4 m | 15.2 m | 7.4 m | 10.6 m | SEC (XBRL)· 09 Mar 2026verified |
| Long-term debt | 10.2 m | 8.0 m | 0 | 0 | 4.3 m | 2.5 m | SEC (XBRL)· 09 Mar 2026verified |
| Current liabilities | 47.3 m | 69.1 m | 66.6 m | 45.1 m | 37.0 m | 44.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Total liabilities | 60.9 m | 84.9 m | 68.7 m | 73.8 m | 66.9 m | 50.2 m | SEC (XBRL)· 09 Mar 2026verified |
| Equity | -68.0 m † | 55.2 m † | -10.6 m † | -37.8 m † | -30.4 m † | 19.0 m † | SEC (XBRL)· 09 Mar 2026verified |
† equity attributable to the parent's shareholders: in these years the issuer no longer reports the total including non-controlling interests.
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -129.0 k | -40.6 m | -81.4 m | -23.5 m | -11.2 m | -10.8 m | SEC (XBRL)· 09 Mar 2026verified |
| Capex | 967.0 k | 969.0 k | 636.0 k | 16.0 k | 35.0 k | 273.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Free cash flow | -1.1 m ≈ | -41.5 m ≈ | -82.0 m ≈ | -23.5 m ≈ | -11.2 m ≈ | -11.1 m ≈ | SEC (XBRL)· 09 Mar 2026derived |
| Investing cash flow | -1.1 m | -2.0 m | -1.6 m | -59.0 k | -761.0 k | -943.0 k | SEC (XBRL)· 09 Mar 2026verified |
| Financing cash flow | 6.5 m | 120.6 m | -878.0 k | 28.9 m | 16.0 m | 32.1 m | SEC (XBRL)· 09 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- indicators available: 5 of at least 6
- score weight coverage: 33.3% of at least 60%
- valuation methods computed: 0 of at least 1
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 132.4 m USD
Key indicators
Coverage and freshness
Score by group
33% · Insufficient data
Estimated value range
unavailable — no valuation method could be computed
Valuation assumptions are editorial choices, not measured; beta is not measured.
Valuation methods
- DCF (discounted cash flow)unavailable · the base of the ratio is not positive
- Peers: EV/EBITDAunavailable · the base of the ratio is not positive
- Peers: P/Eunavailable · the base of the ratio is not positive
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
no valuation method could be computed
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | -7.7% | 38 (vs peers) | 19% |
| FCF conversion · Quality | unavailable | unavailable | — |
| Revenue CAGR 3Y · Growth | 15.2% | 100 (on a fixed band) | 25% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | -56.8x | 0 (on a fixed band) | 19% |
| Current ratio · Balance sheet | 1.6x | 70 (on a fixed band) | 13% |
| P/E (TTM) · Valuation | unavailable | unavailable | — |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | -6.4% | 0 (on a fixed band) | 25% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet28/100 · 2/3 factors with a value
- Growth· partial100/100 · 1/2 factors with a value
- Quality· partial38/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation· partial0/100 · 1/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
OWLET, INC. (OWLT). Latest full fiscal year: 2025; data up to 2026-06-30.
Figures computed from the financial statements: revenue 105.7 m USD in 2025; YoY growth 35.4%; net margin -7.7%.
Valuation cannot be computed from the available data.
Insufficient data for a verdict (indicators available: 5 of at least 6; score weight coverage: 33.3% of at least 60%; valuation methods computed: 0 of at least 1).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Revenue CAGR 3Y: 15.2%
- Current ratio: 1.6x
What contradicts it
- Interest coverage: -56.8x
- FCF yield: -6.4%
Not assessed (insufficient data or a ratio without meaning): ROIC, FCF conversion, EPS CAGR 3Y, Net debt / EBITDA, P/E (TTM), EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Measuring & Controlling Devices, NEC (SIC 3829) · same industry (4-digit SIC) · compared with 9 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| TMOThermo Fisher Scientific Inc. | 261.6 bn | 37.3 | 13.4% | 14.9% | +3.9% | +20% / +42% |
| ROKRockwell Automation, Inc. | 49.3 bn | 41.6 | 34.5% | 13.4% | +0.9% | +12% / +61% |
| TRMBTrimble Inc. | 12.4 bn | — | -2.9% | -4.1% | −2.6% | −33% / +17% |
| ONTOOnto Innovation Inc. | 9.1 bn | 69.4 | 6.8% | 11.8% | unavailable | +29% / +31% |
| MIRMirion Technologies, Inc. | 336.9 m | 159.4 | 1.6% | 2.7% | +7.5% | −31% / +101% |
| OWLTOwlet, Inc. | 132.4 m | — | — | -7.7% | +35.4% | −45% / +5% |
| GEOSGeospace Technologies Corp | 51.0 m | — | -34.4% | -43.1% | −18.3% | −70% / −67% |
| BCHTBirchtech Corp. | 28.9 m | — | -134.4% | -21.7% | +1.3% | −75% / −78% |
| QSIQuantum-Si Incorporated | — | — | -49.1% | -6,138.3% | −20.3% | −9% / −20% |
| NIKINiki BioSolutions, Inc. | — | — | -6.2% | — | −66.7% | −87% / −90% |
1- and 3-year price returns: for OWLT from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Illustrative: not forecasts and without probabilities. Each case is one coherent set of assumptions, computed on today's figures.
Estimated price (USD)
| Estimated price | Bear | Base | Bull |
|---|---|---|---|
| 1 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 3 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
| 5 years | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable | insufficient data Total return unavailable · Per year unavailable |
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
In brief
Owlet is a pediatric health platform that sells FDA-cleared wearable monitors for home use, paired with a subscription service built on pediatric sleep and health data. The company grew revenue 35.4% in fiscal 2025, reported its first full year of positive Adjusted EBITDA, and in the first half of 2026 shifted its focus toward growing its subscriber base 13.
SWOT
Strengths
- Owlet is the only pediatric wearable monitor with FDA authorization and international certifications, and its pediatric data set is considered one of the largest in the field 1.
- The company reached its first positive Adjusted EBITDA full year in 2025 and reported a record quarter in 2026, pointing to improving operating efficiency 13.
- Sales channels are diversified, from direct and retail sales to medical distribution, which reduces reliance on any single channel 1.
Weaknesses
- The company has reported repeated net losses and a significant accumulated deficit, which limits financial flexibility 1.
- Variable-rate debt and liquidity covenants restrict the company's operations and expose it to repayment risk if covenants are breached 1.
- Its operating history at the current scale is limited, which makes financial forecasting and planning harder 1.
Opportunities
- Growth in Owlet360 subscribers could turn revenue into a more recurring and predictable stream with better margins 3.
- International expansion, including the planned launch in India, could open new markets for already authorized products 1.
- Insurance reimbursement and hospital partnerships could broaden access to the medical BabySat monitor 1.
Threats
- Trade tariffs and supply chain restrictions could continue to pressure costs and margins 13.
- Entry of competitors with similar products but without FDA clearance could pressure prices and market share 1.
- Changes in regulation or data protection rules could impose costly new requirements on the digital platform 1.
Risks
- History of losseshigh
The company has not yet reached sustained profitability, and future losses could limit its ability to obtain financing 1.
- Debt and covenantshigh
Breach of liquidity covenants in the credit agreements could lead lenders to accelerate amounts owed 1.
- Tariffs and costsmedium
High tariffs could keep weighing on margins and cash flows if they persist 13.
- Dilution from new equitymedium
If the company issues new shares to fund growth, existing shareholders could face significant dilution 1.
- Reliance on app storeslow
Products depend on apps distributed through the Apple and Google stores, which could expose the company to changes in their policies 1.
Investment thesis
What would need to be true (bull case)
- If Owlet360 subscription growth continues, recurring revenue could become a larger part of the business with better margins 3.
- FDA and international authorizations create a regulatory barrier that rivals may find hard to clear quickly 1.
- Rapid sales growth in fiscal 2025 and in the second quarter of 2026 suggests real demand for the company's products 13.
What would break the thesis
- The company has not yet shown sustainable profitability, and positive results could prove temporary if they depend on one-time items 3.
- Debt and liquidity covenants could limit financial room to maneuver if revenue falls or costs rise 1.
- If tariffs and supply costs stay high, margins could remain under pressure over the long term 13.
What to watch
- Growth in Owlet360 subscribers and subscription revenueQ3 2026
- Delivery against the fiscal 2026 revenue outlook of 118 to 122 million dollars2026
- Effect of tariffs and tariff refunds on gross marginQ3 2026
- India launch and expansion of the medical channel2026
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
The business
Owlet describes itself as a pediatric health platform that brings hospital-grade technology into the family home through medically certified wearable monitors 1. Its ecosystem combines monitoring systems, an integrated video platform and a mobile app, with main products Dream Sock, BabySat, Dream Sight and Dream Duo 1. The company is moving from a hardware-centric business toward recurring revenue from the Owlet360 subscription, launched in January 2025 1.
Segments
Hardware and monitors
Sales of devices, especially Dream Sock and Dream Duo, were the main driver of revenue growth in fiscal 2025, while BabySat targets the medical channel and insurance reimbursement 1. In the first half of 2026, hardware revenue rose 8.8% 2.
Medical channel
The company is expanding distribution through hospitals, insurers and Medicaid programs, including a consignment agreement with a children's hospital and reimbursement in multiple states 1. This channel is still developing and does not yet carry a large share of reported revenue.
Market context
Owlet operates in the United States, Europe, Australia and Canada, where over 33 million infants are born each year, with a launch in India planned for 2026 1. The company argues that baby care spending has stayed resilient through broader economic swings, but the digital pediatric monitoring market is relatively new and contested.
Trends
- Regulatory authorizationtailwind
FDA authorization of a wearable monitor without a prescription has set a high bar for new entrants, since comparable products with medical applications could need similar approvals 1.
- Subscription modeltailwind
Growth in digital services and subscriptions could improve recurring revenue and gross margin, as seen in the second quarter of 2026 3.
- Tariffsheadwind
Tariffs announced in 2025 weighed on cost of goods sold and margins, and if elevated tariff rates persist, cash flows could continue to be affected 1.
- Falling birth ratesmixed
Declining birth rates in some regions could limit long-term demand, although the company believes spending on newborn care has continued to rise 1.
Competitive position
Competition ranges from established players to emerging innovators, including companies that sell sound and video monitors not cleared by the FDA 1. Owlet says it is the only company offering a baby monitor with FDA clearance alongside multiple international certifications 1.
- Established baby audio and video monitor makers
Companies selling non-medical baby monitors without FDA clearance, competing in the general monitor segment 1.
- Emerging digital monitoring innovators
Newer entrants in pediatric digital health, referenced in the competition discussion without product detail 1.
- Sellers of non-medical products
Companies selling monitoring systems without medical certification, competing directly on price and sales channels 1.
- Retail and e-commerce channels
Major retail platforms act both as distribution channels and as arenas where similar products compete 1.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report14 Aug 2026Departure or appointment of officers · Shareholder vote · Financial statements and exhibits
- Quarterly report14 Aug 2026
- Current report11 Aug 2026Results of operations · Financial statements and exhibits
- Current report01 Jul 2026Material agreement · Creation of a direct financial obligation · Financial statements and exhibits
- Proxy statement30 Jun 2026
- Current report05 Jun 2026Other events
- Quarterly report11 May 2026
- Current report07 May 2026Results of operations · Financial statements and exhibits
- Current report06 Apr 2026Departure or appointment of officers · Financial statements and exhibits
- Annual report09 Mar 2026
Sources
- [1] Form 10-K, fiscal year ended 2025-12-31 · SEC / Owlet, Inc. · 09 Mar 2026
- [2] Form 10-Q, quarter ended 2026-06-30 · SEC / Owlet, Inc. · 14 Aug 2026
- [3] Form 8-K, results release (exhibit 99.1) · SEC / Owlet, Inc. · 11 Aug 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.